NFKB1 and plasma cell myeloma: The reason for the specificity of bortezomib against multiple myeloma cells could be due to the inhibitory effect on the nuclear factor (NF)-kB pathway (by inhibiting proteasome degradation of the NF-kB inhibitor IkB) [35].